Friedl-Naderer Johanna sold $6K of DYN
Friedl-Naderer Johanna (Chief Commercial Officer) sold 226 shares of Dyne Therapeutics, Inc. (DYN) at $26.28 on 2026-08-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale details: 226 shares sold at $26.2800 on 2026-08-13, with holdings after transaction of 153,982 shares, under a pre-arranged 10b5-1 plan.
Market read
This provides incremental transparency on insider trading but is unlikely to materially change valuation expectations by itself.
What to watch
The filing does not indicate reasons for sale, and 10b5-1 plans are designed to reduce timing-based signaling.
Background
The article is a SEC Form 4 insider transaction disclosure for Dyne Therapeutics, Inc.
Ticker impact
Dyne Therapeutics disclosed a Form 4 showing CCO Johanna Friedl-Naderer sold 226 shares at $26.28 on 2026-08-13 under a 10b5-1 plan.
Low likelihood of a sustained price move based solely on this transaction; any reaction would likely be short-lived.
The filing is an open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, and the disclosed value is modest ($5,939.28).
Market effects
No clear sector read-through from a small, planned insider sale.
None indicated.
None indicated.
Counterpoint
Even planned 10b5-1 sales can coincide with internal views on liquidity or risk, so traders may still watch for follow-on insider activity.
Key entities
- issuerDyne Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderFriedl-Naderer Johanna
Chief Commercial Officer who sold 226 shares.
